Belviq Gains FDA Approval For Weight Loss, But DEA Review Will Delay Launch
This article was originally published in The Pink Sheet Daily
Executive Summary
With a July 17 user fee date, Vivus’ obesity drug Qnexa could beat Arena Pharmaceuticals’ Belviq to the marketplace as lorcaserin awaits controlled substance scheduling by the Drug Enforcement Agency.